The economic consequences of Alzheimer's disease in the context of new drug developments.
The first national symptomatic treatment for Alzheimer's disease has received a very mixed and perhaps ageist reception from purchasers of health care in the UK. This is largely because detailed information on the long-term effects of this class of drugs is scarce. However, by looking at the published evidence on the economic burden of Alzheimer's disease, some observations and assumptions can be made as to the influence of the new drug treatments. The drug therapies available and those most likely to become licensed are reviewed and the potential economic impact is discussed. Long-term outcome studies would properly address this, but as these drugs have now demonstrated efficacy, particularly in non-cognitive behaviours, it will be ethically more difficult to maintain patients on placebo for long periods. Some assumptions therefore have to be made from long-term open-label studies. Those drugs currently available, and those in development, may offer effective treatment for some of the core symptoms of Alzheimer's disease, slowing the rate of cognitive decline and preserving competence in activities of daily living for longer. If handled correctly, these treatments have the potential to offer cost savings for many patients, and cost-effectiveness improvements look probable.
Knapp
M
M
Personal Social Services Research Unit, London School of Economics and Political Science, UK. M.Knapp@lse.ac.uk
Wilkinson
D
D
Wigglesworth
R
R
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy / Q000191:economics*; D002800:Cholinesterase Inhibitors / Q000191:economics / Q000627:therapeutic use; D003071:Cognition / Q000187:drug effects; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D004358:Drug Therapy / Q000191:economics*; D005544:Forecasting; D017048:Health Care Costs; D006801:Humans; D006113:United Kingdom
D002800:Cholinesterase Inhibitors